Aim-To study changes induced in ocular surface epithelia and the tear film by antiglaucomatous eyedrops. A blocker (0.5% timolol) and a novel prostaglandin F 2 metabolite related drug (0.12% unoprostone) were examined in a prospective, randomised fashion. Methods-40 patients were randomly assigned to use either 0.5% timolol (timolol group) or 0.12% unoprostone eyedrops (unoprostone group) twice a day for 24 weeks. In addition to routine ocular examinations, corneal epithelial integrity (vital staining tests, tear film break up time (BUT), anterior fluorometry, specular microscopy) and tear function (Schirmer's test, cotton thread test, tear clearance test (TCT)) were examined before and after the treatment. Results-Both eyedrops caused significant reduction in intraocular pressure from the baseline levels. No significant changes were noted in corneal integrity in both groups, except a decrease in BUT at 20 weeks in the timolol group. The timolol group demonstrated significant decreases in Schirmer's test, tear clearance test, and tear function index (Schirmer's test value multiplied by clearance test); however, no such changes were noted in the unoprostone group. Conclusion-While unoprostone eyedrops caused no adverse eVects on the corneal epithelial integrity and tear function, timolol caused significant impairments in tear production and turnover. (Br J Ophthalmol 2000;84:1250-1254 The past 10 years has witnessed the development of a number of antiglaucomatous eyedrops such as blockers, adrenergic stimulants, carbonic anhydrase inhibitors, and prostaglandin analogues. While these new drugs expanded the choice of treatment, they also increased risks of drug related complications. Since antiglaucomatous eyedrops are used for a long period of time, chronic side eVects are a major concern. Among these side eVects, ocular surface disorders are relatively common, which are caused by either the drug itself or by preservatives. [1][2][3] This complication has recently attracted attention in Japan, especially since a prostaglandin F metabolite related drug, unoprostone, was introduced.
4-7The incidence of corneal complications is reported to be up to 12.9% of patients using unoprostone eyedrops.
8-11It is not clear, however, if unoprostone is truly responsible for the complication because many of these patients had been using other antiglaucomatous eyedrops-namely, blockers. It has been reported that blockers alter corneal sensitivity and ocular surface epithelia.12-15 Therefore, it is not clear whether or not the ocular surface complications in glaucoma patients are attributed to the use of unoprostone, blockers, or the combination of both. We conducted a randomised, prospective comparative study on the changes in ocular surface epithelia and tear functions in patients who used either unoprostone or timolol eyedrops.
Subjects and methods
PATIENTSForty patients with primary open angle glaucoma (n=8), normal tension glaucoma (n=6), or ocular hypertension (n=26) were enrolled in this open labelled, randomised pro...